These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 25130507)
21. Reflections on the Nobel Prize for Medicine 2015--The Public Health Legacy and Impact of Avermectin and Artemisinin. Molyneux DH; Ward SA Trends Parasitol; 2015 Dec; 31(12):605-607. PubMed ID: 26552892 [TBL] [Abstract][Full Text] [Related]
23. A New Golden Age of Natural Products Drug Discovery. Shen B Cell; 2015 Dec; 163(6):1297-300. PubMed ID: 26638061 [TBL] [Abstract][Full Text] [Related]
24. A theoretical flaw in the advance market commitment idea. Sonderholm J J Med Ethics; 2010 Jun; 36(6):339-43. PubMed ID: 20530089 [TBL] [Abstract][Full Text] [Related]
25. The life and times of ivermectin - a success story. Omura S; Crump A Nat Rev Microbiol; 2004 Dec; 2(12):984-9. PubMed ID: 15550944 [TBL] [Abstract][Full Text] [Related]
26. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. Thylefors B; Alleman MM; Twum-Danso NA Trop Med Int Health; 2008 May; 13(5):689-96. PubMed ID: 18419585 [TBL] [Abstract][Full Text] [Related]
27. Impact of ivermectin on illness and disability associated with onchocerciasis. Tielsch JM; Beeche A Trop Med Int Health; 2004 Apr; 9(4):A45-56. PubMed ID: 15078278 [TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of Mectizan distribution. Waters HR; Rehwinkel JA; Burnham G Trop Med Int Health; 2004 Apr; 9(4):A16-25. PubMed ID: 15078276 [TBL] [Abstract][Full Text] [Related]
29. Onchocerciasis control: the APOC strategy. Dadzie KY Afr Health; 1997 Mar; 19(3):13-5. PubMed ID: 12292398 [TBL] [Abstract][Full Text] [Related]
30. Endectocidal drugs: ecological risks and counter-measures. Herd R Int J Parasitol; 1995 Aug; 25(8):875-85. PubMed ID: 8550287 [No Abstract] [Full Text] [Related]
31. Control of onchocerciasis. Boatin BA; Richards FO Adv Parasitol; 2006; 61():349-94. PubMed ID: 16735169 [TBL] [Abstract][Full Text] [Related]
32. Making a difference: 30 years of TDR. Ridley RG; Fletcher ER Nat Rev Microbiol; 2008 May; 6(5):401-7. PubMed ID: 18414503 [TBL] [Abstract][Full Text] [Related]
33. Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases. Ang CW; Jarrad AM; Cooper MA; Blaskovich MAT J Med Chem; 2017 Sep; 60(18):7636-7657. PubMed ID: 28463485 [TBL] [Abstract][Full Text] [Related]
34. Mectizan Donation Program: evaluation of a public-private partnership. Peters DH; Phillips T Trop Med Int Health; 2004 Apr; 9(4):A4-15. PubMed ID: 15078275 [TBL] [Abstract][Full Text] [Related]
35. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Campbell WC Curr Pharm Biotechnol; 2012 May; 13(6):853-65. PubMed ID: 22039784 [TBL] [Abstract][Full Text] [Related]
36. Endemicity of onchocerciasis in some local government areas of Niger state. Idowu ET; Adewale B; Mafe MA; Appelt B; Bamgbose A Afr J Med Med Sci; 2004 Mar; 33(1):31-4. PubMed ID: 15490791 [TBL] [Abstract][Full Text] [Related]
37. The delivery of ivermectin (Mectizan). Burnham G; Mebrahtu T Trop Med Int Health; 2004 Apr; 9(4):A26-44. PubMed ID: 15078277 [TBL] [Abstract][Full Text] [Related]
38. Current world literature. Curr Opin Infect Dis; 2012 Dec; 25(6):718-28. PubMed ID: 23147811 [No Abstract] [Full Text] [Related]
39. Developing drugs for parasitic diseases. Andreopoulos S Science; 2003 Apr; 300(5618):430-1. PubMed ID: 12702858 [No Abstract] [Full Text] [Related]
40. Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis. Abanobi OC; Chukwuocha UM; Onwuiiliri CO; Opara KC East Afr J Public Health; 2011 Mar; 8(1):33-7. PubMed ID: 22066280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]